Combined Effect Of EU Pediatrics And Orphan Drugs Legislation Under EU Commission Scrutiny

A joint evaluation of the EU pediatrics and orphan drugs legislation is due to commence next year in an effort to understand why the two legal instruments have failed to encourage companies to develop medicines targeting rare diseases in children. The initiative will help decide the possible need for future changes.

Vaccination
There Will Be A Joint Examination Of EU Laws On Pediatrics And Orphan Drugs • Source: Shutterstock

The European Commission has announced plans to undertake a joint evaluation of the EU pediatric and orphan drugs legislation to determine why the combined effects of these legal instruments have failed to deliver major therapeutic advances in diseases that are rare and/or unique in children.

To support the evaluation, the commission has published a three-page roadmap explaining the content, purpose and scope of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Rare Diseases

More from Pink Sheet